---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-302660"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2026-07-14T13:20:16+00:00"
generated_at: "2026-07-14T13:21:21.663195+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Ligand completes acquisition of XOMA Royalty for $739M; portfolio exceeds 200 assets

## Summary
- Total equity value ~$739M; XOMA Royalty stockholders received $39/share cash plus one CVR per share.
- Adds seven commercial products including VABYSMO, OJEMDA, and MIPLYFFA, plus 14 late-stage programs.
- Portfolio more than doubled to over 200 commercial, clinical, and preclinical royalty assets.
- Transaction expected to add ~$0.50 to 2026 and ~$1.50 to 2027 adjusted EPS; accretive immediately.
- New $125M revolving credit facility with maturity Sept 2028; covenants include min EBITDA of $100M-$150M.

## SEC filing metadata
- accession: 0001193125-26-302660
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2026-07-14T13:20:16+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000119312526302660/0001193125-26-302660-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000119312526302660/d108457d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-302660
- JSON: https://secwatch.observer/filing/0001193125-26-302660.json
- Plain text: https://secwatch.observer/filing/0001193125-26-302660.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.